The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Tumor microRNA-29a expression and the risk of recurrence in stage II colon cancer.
Ofer Purim
No relevant relationships to disclose
Alina Weismann-Brenner
No relevant relationships to disclose
Michal Kushnir
Employment or Leadership Position - Rosetta Genomics
Gila Lithwick-Yanai
Employment or Leadership Position - Rosetta Genomics
Ranit T. Aharonov
Employment or Leadership Position - Rosetta Genomics
Hadas Gibori
Employment or Leadership Position - Rosetta Genomics
Yulia Kundel
No relevant relationships to disclose
Sara Morgenstern
No relevant relationships to disclose
Marisa Halpern
No relevant relationships to disclose
Yaron Niv
No relevant relationships to disclose
Baruch Brenner
Consultant or Advisory Role - Rosetta Genomics